Pre-emptive Detection And Evolution Of Relapse In Acute Myeloid Leukemia By Flow Cytometric Measurable Residual Disease Surveillance

This article discusses the use of flow cytometry MRD (minimal residual disease) testing for detecting impending relapse in patients with acute myeloid leukemia (AML). The study found that MRD testing had a diagnostic sensitivity of 64% for detecting relapse within 2-4 months, with a specificity of 9% in non-relapsing patients. The results suggest that flow cytometry MRD testing may be a useful tool for monitoring AML patients for relapse.